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ABSTRACT  
Back ground: Chronic Kidney Disease (CKD) is the most common health related problem. Poor long term adherence is the major clinical issue 
in the management of CKD. Therefore good medication adherence is important to obtain desired therapeutic outcome which in turn improves 
the quality of life of the patient. The aim of the study is to carry out a study on medication adherence and to improve health related quality of 
life in patients with CKD. 
Objectives: To evaluate medication adherence and to assess the factors associated with non adherence and to provide patient counselling t o 
improve medication adherence and to improve their quality of life.  
Methods: A prospective study conducted for a period of six months in NU Hospitals Bengaluru. A total of 140 patients (62 were undergoing 
hemodialysis, 66 were CKD stage 3-5 and 12 were post-transplant patients) were enrolled for the study. Patient’s adherence to medication was 
assessed with the help of Modified Morisky, Green, Levine Medication Adherence Scale and Quality of life was assessed with the help of Kidney 
Disease Quality of Life-Short Form 36 questionnaire. One to one follow up was done after 3 months of initial data collection.  
Results: During the study 140 patients were enrolled for the study with 103 males and 37 females. Patient with low and medium adherenc e 
during the first visit were 7 (5%) and 21 (45%) respectively and patients with high adherence during baseline visit were 80%, which later 
improved to 85.7% in the final review after patient counselling. Quality of life is decreased in patients with CKD. The domai n with highest 
average score was emotional well being (8.4) and lowest average score was role limitation due to physical health (4.12). There was a slight 
improvement in Quality of Life of the patients after patient counselling.  
Conclusion: Study suggests that patient counselling by clinical pharmacists can improve the medication adherence by improving awareness 
about medication which in turn helps them to achieve a better quality of life.  
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INTRODUCTION 
Chronic nephropathy (CKD) conjointly referred to as chronic 
nephrosis or progressive nephropathy or uropathy. It is 
defined as the presence of excretory organ harm or ablated 
capillary Filtration Rate (GFR). CKD could be a progressive 
un-wellness that eventually ends up in nephropathy known 
as End-Stage excretory organ diseases (ESRD). Therefore 
early detection, management and treatment is considered in 
minimizing morbidity and mortality1. The incidence of CKD 
has doubled in last 15years. CKD has become a pestilent as 
a result of sophisticated interrelationships with DM, high 
blood pressure and different associated diseases2. 
CKD patients belongs to the subjects with daily pill load 
up to twenty pills per day relying upon the severity of the 
disease; such a high pill burden is inevitably related 
to major issues of drug adherence3. 
Adherence to medication: 
Adherence to medication is the extent to that the patient’s 
behaviour matches with the recommendations from the 
prescriber4. World Health Organization (WHO) data shows 
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that only 50% of the individuals with chronic illness take 
their medication properly as suggested. Thus non adherence 
to prescribed medication is related to poor clinical 
outcomes, accelerated illness progression and big economic 
burden to health care system. Therefore, assessment of 
adherence to prescribed treatment plan is very important in 
reducing the complexities of chronic illness. Poor 
compliance is the most typical explanation for failure to 
retort to medications and poor treatment outcomes. Poor 
compliance typically ends up in further unessential tests, 
indefinite quantity changes, emergency department visits 
or medical aid that ultimately leads to inflated cost of 
medical care. In CKD adherence to medication could be 
a key element for effective management. Poor adherence 
and persistence to drug is universally recognized as the 
foremost clinical problems within the management of 
chronic diseases. Non adherence rates among CKD patients 
found in previous studies vary from two to ninety eight 
percent, hence it's necessary to know non adherence to and 
study the factors associated. Many studies showed that 
patient medical education will retard the progression of 
chronic diseases and improve survival, improves sickness 
understanding and boost quality of life4. 
Potential methods to enhance medication adherence in 
CKD patients: 
Strategies to enhance drug adherence in CKD patients need 
to primarily concentrate on the patient and physician’s 
motivations as well as developing trust and sympathy 
providing the maximum patient education on the 
requirement of taking all of those medication. While 
evaluating drug therapies, the main focus should be 
simplifying drug regimens4. 
Quality of life (QOL) in CKD patients: 
World Health Organization (WHO) defines quality of life 
(QOL) as an individual’s perception of their position in 
life within the context of the culture they live and in relation 
to their goals, standards and concerns. It is affected by the 
person’s physical health condition, personal belief, social 
relationship and their relationship to the environment .Most 
conceptualizations of QOL emphasize the results of illness on 
physical, social/role, psychological/emotional, 
and psychological feature functioning. Symptoms, health 
perceptions, and overall quality of life 
are typically enclosed within the domain of QOL5. 
Effective management depends on educating the patient 
about the importance of taking medications which in turn 
improves their medication adherence and thus decreases the 
progression of the disease. By counselling a patient can help 
in achieving increased medication knowledge, decreased 
hospitalization rates and thus improves the overall quality of 
life of the patients 5. 
Objectives 
 To evaluate the adherence to medication and to assess 
the factors associated with non-adherence. 
 To provide patient counselling to improve medication 
adherence and to improve their quality of life. 
MATERIALS AND METHODS 
Study site: 
The study was conducted at NU Hospitals, Padmanabha 
nagar, Bengaluru, Karnataka, India. 
Study design: 
A prospective observational study. 
Study duration: 
This study was carried out for a period of six months.  
Inclusion criteria 
 Patients who are attending hospitals, Nephrology 
outpatient’s department and patients undergoing 
hemodialysis irrespective of co-morbidities. 
 Patients who are above 18 years of age. 
 CKD patients of stage 3-5D (D-dialysis). 
 Renal transplant patients. 
Exclusion criteria 
 Patients who are not willing to give the Informed 
consent. 
 Patients less than 18 years of age. 
 CKD stages 1-2. 
Source of data collection: 
o The data necessary for the study was collected from, 
o Patients case files, 
o Interviewing patients and their care takers. 
Informed consent procedure: 
The study plan was explained in detail to the patient with 
the help of Patient Information Sheet. Informed Consent is 
taken in a format approved by Ethics Committee, NU 
Hospitals in either English/Kannada. Consent form was 
explained to the patient by the investigator before obtaining 
the signature. 
Study procedure: 
After obtaining the Informed consent from the patient, 
information such as demographic details (after hiding the 
patient’s identity), co-morbid factors (hypertension, 
diabetes mellitus, anaemia, cardiovascular disorders etc.), 
medication taken and the frequency of dialysis was collected 
with the help of patient data collection form. Patients GFR 
were calculated using Modification of Diet in Renal Disease 
(MDRD) equation. 
One to one follow up was done after 3 months of initial data 
collection. Patients adherence to medication was assessed 
with the help of Modified Morisky, Green, and Levine 
Medication Adherence Scale approved by Ethics Committee, 
NU Hospitals. The questionnaire contains 8 questions that 
identify the reasons for non-adherence such as: 
 Forgetfulness 
 Carelessness 
 Lack of medication information 
 Fear of side effects 
 Pill burden 
 Cost of drug 
Scores are given according to the answers given by the 
patient. For each question, there are 2 possible answers, YES 
or NO. Adherence score for these 2 answers were set as 
NO=0 and YES=1 except for 7th question were NO=1 and 
YES=0 and for 8th question there are 4 possible answers like 
a) never, b) once in a while, c) sometimes, d) usually, e) all 
the time where a is scored as 0 and b to e is scored as 1. 
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Adherence was calculated based on the total score of the 
medication adherence questionnaire. Scores, >2 indicates 
low adherence, score 1-2 indicates medium adherence and 
score 0 indicates high adherence. The patient’s medication 
adherence decreases as the score of the medication 
adherence questionnaire increases. Quality of life was 
assessed with the help of KDQOL-SF-36. The questionnaire 
contains nine health concepts such as: 
 Physical functioning 
 Role limitation due to physical health 
 Role limitation due to emotional problems 
 Energy/fatigue 
 Emotional well being 
 Social functioning 
 Pain 
 General health and 
 Health change 
Scoring was done using online RAND 36 Score calculator. It 
is a two-step process. First, preceded numeric values are 
recoded, high score defines a more favourable health state. 
In addition, each item is scored on a 0 to 10 range so that the 
lowest and highest possible scores are 0 and 10 respectively. 
Scores represent the percentage of total possible score 
achieved. In step 2, items in the same scale are averaged 
together to create the 9 scale scores. 
Aid used: 
Patient Information Leaflet was taken from American 
Academy of Family Physicians which was given to the 
patients after patient counselling to improve their quality of 
life. It gives out information about the importance of taking 
medicines, lifestyle modification such as exercises and diet. 
Data collection form: 
The data collection form was developed. It includes patient 
demographics, comorbidities, number of medicines taken, 
other medicines taken (OTC, Ayurvedic etc), serum 
creatinine and stages of CKD. 
Statistical analysis: 
 Correlation between medication adherence and quality 
of life was assessed with the help of Pearson 
Correlation. 
 Medication adherence behaviour before and after 
patient education was compared with the help of 
paired sample T-test. 
RESULTS 
A total of 140 patients (62 were undergoing hemodialysis, 
66 were CKD stage 3-5 and 12 were CKD transplant 
patients) were enrolled for the study, out of which 103 were 
males and 37 were females. 
Table 1: Gender wise distribution of patients 
Gender Frequency Percent (%) 
Male 103 73.57 
Female 37 26.42 
Total 140 100.0 
 
Table 2: Patient distribution according to age 
Age Total number of patients (%) 
20-29 7 (5) 
30-39 11 (7.86) 
40-49 13 (9.3) 
50-59 34 (24.28) 
60-69 46 (32.9) 
70-79 25 (17.85) 
80-89 4 (2.85) 
 
Table 3: Patient distribution according to different 
stages of CKD 
Stage Number of patients Percent (%) 
3A 6 4.28 
3B 16 11.42 
4 25 17.85 
5 19 13.57 
5D 62 44.28 
CKD 
Transplant 
12 8.57 
Total 140 100 
 
Table 4: CKD with other co-morbidities 
Comorbity Number of patients (%) 
HTN 132 (94.2) 
DM 86 (6104) 
Anemia 52 (37.1) 
CV Disorder 28 (20) 
Thyroid 21 (15) 
Respiratory disorder 10 (7.14) 
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Figure 1: Graphical representation of CKD with other co-morbidities 
Table 5: Adherence to medication-pre and post counselling 
Adherence Baseline values (%) Post-intervention (after counselling) (%) 
High 112 (80) 120 (85.7) 
Medium 21 (15) 20 (14.3) 
Low 7 (5) 0 
 
 
Figure 2: Graphical representation of Adherence to medication-pre and post counseling 
 
Table 6: Medication adherence-pre and post counselling among male patients 
Adherence Baseline value (%) Post-intervention (after patient counselling) (%) 
High 82 (79.61) 89 (86.40) 
Medium 15 (14.5) 14 (13.59) 
Low 6 (5.82) 0 
 
Table 7:  Medication adherence-pre and post counselling among female patients 
Adherence Baseline values (%) Post-intervention (after counselling) (%) 
High 30 (81.08) 31 (83.78) 
Medium 6 (16.21) 6 (16.21) 
Low 1 (2.70) 0 
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Table 8: Medication adherence-pre and post counselling in different stages of CKD 
 
Table 9: Age wise distribution of medication adherence-pre and post counselling 
 
 
 
Age 
ADHERENCE 
High Medium Low 
Baseline 
values (%) 
Post-intervention 
(after 
counselling) (%) 
Baseline 
values (%) 
Post-intervention 
(after 
counselling) (%) 
Baseline 
values (%) 
Post-intervention 
(after 
counselling) (%) 
20-29 5 (71.4) 6 (85.7) 2 (28.6) 1 (14.3) 0 0 
30-39 8 (72.72) 10 (90.9) 3 (27.3) 1 (9.09) 0 0 
40-49 11 (84.6) 11 (84.6) 2 (15.4) 2 (15.4) 0 0 
50-59 27 (79.4) 28 (82.35) 5 (14.7) 6 (17.64) 2 (5.88) 0 
60-69 36 (78.26) 41 (89.13) 6 (13.04) 5 (10.87) 4 (8.7) 0 
70-79 20 (80) 20 (80) 2 (8.0) 5 (16) 2 (8) 0 
80-89 3 (75) 3 (75) 1 (25) 1 (25) 0 0 
 
Table 10: Reasons for medication non-adherence-pre and post counselling 
Reasons Baseline values (%) Post-intervention (after counselling) (%) 
Forgetfulness 14 (10) 05 (3.57) 
Pill burden 12 (8.57) 12 (8.57) 
Concerned about cost 12 (8.57) 12 (8.57) 
Carelessness 11 (7.85) 05 (3.57) 
Fear of side effects 07 (5) 0 
Lack of information 06 (4.28) 01 (0.71) 
 
 
Figure 3: Graphical representation of reasons for medication non adherence-pre and post counselling 
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CKD 
Stage 
High adhered Medium adhered Low adhered 
Baseline 
values (%) 
Post-intervention 
(after 
counselling) (%) 
Baseline 
values (%) 
Post-intervention 
(after counselling) 
(%) 
Baseline 
values (%) 
Post-intervention 
(after 
counselling) (%) 
3 to 5 49 (74.2) 52 (78.8) 12 (18.2) 10 (15.15) 2 (3.03) 0 
5D 49 (79) 52 (80.9) 8 (13) 10 (16.13) 5 (8.06) 0 
PT 11 (91.7) 11 (91.7) 1 (8.33) 1 (8.33) 0 0 
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Table 11: Number of pills taken by the patients 
Number of pills Number of patients (%) 
1 to 5 21 (15) 
6 to 10 69 (49) 
11 to 15 44 (32) 
>15 6 (4) 
 
Table 12: Quality of life of patients-pre and post counselling 
S. No. Quality of life Mean value before 
education 
Mean value after 
education 
1 Emotional well being (EWB) 8.4 8.46 
2 Pain 8.12 8.23 
3 Social functioning (SF) 7.30 7.43 
4 Physical functioning (PF) 6.49 6.51 
5 Energy/fatigue (E/F) 6.30 6.36 
6 Role limitation to emotional problem 
(RLEP) 
6.25 5.98 
7 Health change (HC) 5.94 6.07 
8 General health (GH) 5.88 5.41 
9 Role limitation to physical health (RLPH) 4.12 4.28 
  
Table 13: Quality of life in association with age and medication adherence-pre and post counselling 
 
Age (years) 
High adherence Medium adherence Low adherence 
Baseline values Post-
intervention 
(after 
counselling) 
Base line values Post-
intervention 
(after 
counselling) 
Base line 
values 
Post-intervention 
(after counselling) 
20-29 7.60 7.62 6.65 8.3 - - 
30-39 7.04 7 7.74 7.8 - - 
40-49 6.78 7.04 7.53 7.8 - - 
50-59 6.36 6.82 6.26 6.2 5.82 - 
60-69 6.31 6.66 6.15 6.4 5.27 - 
70-79 6.32 6.3 4.80 4.8 4.20 - 
80-89 6.93 6.94 7 7 - - 
 
Table 14: Medication adherence before and after patient counselling 
Paired Samples Correlations: 
 N Correlation Sig. 
Pair 1: Pre-adherence and post-adherence 140 0.814 0.000 
 
Paired Sample Statistics: 
  Mean N Std. Deviation Std. Error Mean 
Pair 1 Pre-adherence 0.44 140 0.969 0.082 
Post-adherence 0.26 140 0.653 0.055 
 
Paired sample test: 
 
 
Pair 1 
 
Paired differences  
 
T 
 
 
DF 
 
 
Sig. (2-
Tailed) 
Mean Std. 
Deviation 
Std. 
Error of 
Mean 
95%  Confidence interval 
of the difference 
Lower Upper 
Pre-adherence 
and post-
adherence 
0.170 0.579 0.049 0.082 0.0275 3.652 139.00 0.000368048 
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DISCUSSION 
Chronic Kidney Disease (CKD), also known as chronic renal 
insufficiency, progressive kidney disease, or nephropathy, 
and it is defined as the presence of kidney damage or 
decreased Glomerular Filtration Rate (GFR) for 3months or 
more. CKD is a progressive disease that eventually leads to 
renal failure called End-Stage Renal diseases (ESRD). 
Therefore, effective management depends on making patient 
adhered to their medication. Good medication adherence is 
important to achieve desired therapeutic outcome whereas 
low adherence is considered as one of the major reason for 
decreased therapeutic outcome. 
The aim was to evaluate medication adherence and to 
improve health related quality of life in patients with 
Chronic Kidney Disease. The study was done in NU Hospitals 
Bengaluru, Karnataka. The study was carried out for a 
period of 6 months from November 2018-April 2019, a total 
of 152 patients were included in the study. Out of 152 
patients, 12 were excluded due to lack of follow up. 
Therefore, valuable data obtained was of 140 patients. 
Our study included 140 patients as shown in Table 1, 103 
were found to be male, 37 were found to be female and 
overall age group of patients range from 20-80 years of 
mean age 57.74 ± 14.047. 
As shown in Table 2, in the age group of 20 to 29 years 7 
(5%), in the age group 30-39 years 11 (7.86%), in the age 
group 40-49 years, 13 (9.3%), in the age group 50-59 years, 
34 (24.28%), in the age group 60-69 years, 46 (32.9%) in the 
age group 70-79 years age group, 25 (17.85%) and in the 
age group of 80 to 89, 4 (2.85%) patients were found. 
Highest percentage of patients was found in the age group of 
50-70 years. 
In a study conducted by Syeda Firdous, Ayesh Siddiqua et.al. 
on “Assessment of risk factors and medication adherence of 
CKD”, it was found that 41-50 years of age group patients 
were more adhered i.e. 92 (30.%) as compared to remaining 
age groups4. 
In current study as shown in Table 3, it was found that 
15.7% belong to CKD stage 3, 17.85% belong to CKD stage 4, 
13.57% belong to CKD stage 5, 44.28% were on 
haemodialysis and 8.57% were CKD transplant patients. 
Siva Kala T, Arepalli Sreedevi, Hari Prasad MV, Jikki PN 
conducted a study on “Assessment of knowledge and 
adherence to therapy among CKD patients“. It was observed 
that 68.9% were in stage 5, 15.53% stage 4, 11% were stage 
3 among which 85% patients were found to be on HD6. 
Out of 140 patients included in our study, as shown in Table 
4 it was found that the comorbidity associated with CKD was 
HTN (94.2%), DM (61.4%), anemia (37.1%), cardiovascular 
disease (20%), thyroid (15%) and respiratory disorder 
(7.14%). In our study, it was found that 132 out of 140 
patients had HTN (94.2%) than any other co-morbidity. 
In a previous study by Olumuyiwa J.F, Peter Ehizokhale 
Akhideno, Oluwatosin Beatrice Ibiyemi-Fasipe et. al. on “The 
burden of polypharmacy and pattern of comorbidities 
among chronic kidney disease patients in clinical practice” it 
was observed that the main co-morbidity associated with 
CKD were HTN (83.70%), DM (31.70%), Coronary Heart 
Disease (8.90%) and obesity (19.51%)7. 
Out of 140 patients, as shown in Table 5, high adherence was 
found in 112 (80%), medium adherence was found in 21 
(45%) and low adherence was found in 7 (5%) prior to 
education. For patients whose medication adherence was 
low during the baseline visit which was improved by patient 
education through counselling. Patient with low and 
medium adherence during the first visit were 7 (5%) and 21 
(45%) which were gradually reduced and patients with high 
adherence during baseline visit were 80%, which later 
improved to 85.7% in the final review. 
In a study conducted by W. Tesfaye, R. Castelino et.al. on 
“Medication adherence in adults with advanced Chronic 
Kidney Disease”, it was observed that 35 patients out of 78 
were found to be non adhered ( 45%) and 55% patients 
were found to be adhered8. 
In this study as shown in Table 6and 7, it was found that 
small range of significant difference exist between 
medication adherence in male and female i.e., females were 
found to be more adhered to medication by 81.08% than 
male 79.61%. 
A similar study conducted by Yoke Mun Chan, Mohd Shariff 
et.al. on “Determinants of compliance behaviour among 
patients undergoing haemodialysis”, it was found that there 
were no significant difference between male and female 
subjects on medication compliance9. 
Out of 140 patients included in our study as shown in Table 
8, CKD transplant patients were found to be more adhered 
than patients undergoing dialysis and patients of CKD stages 
3-5. 
In a study conducted by Rajiv Ahlawat, Pramil Tiwari and 
Sanjay D Cruz, on “Prevalence and predictors of medication 
non adherence in patients of CKD”, it was found that patients 
on haemodialysis were more likely to be non-adherent to 
medications compared to other stages of CKD10. 
In our study it was found that as shown in Table 9, younger 
adults of age group 20-29 years were less adhered to their 
medication regimen compared to older age and also 
medication adherence was improved after effective patient 
education through counselling. 
In a previous study conducted by Tangkiatkumjai M, Walker 
D M et. al. on “Association between medication adherence 
and clinical outcomes in patients with CKD”. It was found 
that patients in the younger age group 28-39 years reported 
medication non-adherence at higher rate (38%) than 
patients over 60 years (21%)11. 
In present study, as shown in Table 10, it was found that the 
most common reason for non-adherence was forgetfulness 
(10%), carelessness (7.85), concern about cost (8.57%), pill 
burden (8.57%), fear of side effect (5%) and the least 
effected factor was lack of information (4.28%). After patient 
education, it was found that forgetfulness reduced to 3.57%, 
carelessness reduced to 3.57%, fear of side effects was 0 and 
lack of information reduced to 0.71%. But there was no 
change found in pill burden and concern in cost. 
In a study conducted by Bhupendra Verma, Amrita Singh, J. 
S. Bishnoi, Anil Kumar Mishra conducted a study on 
“Adherence to medication in chronic kidney disease“. It was 
found that High cost of medications (72%) and need to take 
medicines for long durations (59%) were among the most 
common types of non-adherence. High pill burden and 
complex dosing schedule were other common causes of non-
adherence in this study. Prescription of ≥ 4-5 pills/day has 
been significantly associated with non-adherence in CKD 
patients. Fear of adverse effects of medications, lack of 
knowledge about necessity of individual drug, and lack of 
knowledge and insight about nature of disease were other 
important factors12. 
In our study, as shown in Table 11, out of 140 patients, it 
was found that 21 patients had a daily pill load of 1 to 5, 69 
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patients had a pill load of 6-10, 4 patients had a pill load of 
11-15 and 6 patients had >15 pill load.  
In a study conducted by Yi-Wen Chiu , Isaac Teitelbaum, 
Madhukar Misra on “Pill burden, adherence, 
hyperphosphatemia, and quality of life in maintenance 
dialysis patients”. It was observed that the oral medications 
contributed to a median daily pill burden of 19. The daily pill 
burden exceeded 10 in 91% of subjects, was more than 20 in 
47%, and more than 30 in 17%13. 
Quality of Life was assessed for 140 patients before and after 
patient counselling. It was found that as shown in Table 12 
after patient counselling there was a slight improvement in 
Quality of Life of the patients with CKD. The domain with 
highest average score was Emotional well being (8.4) and 
lowest average score was role limitation due to physical 
health (4.12). 
In a study conducted by Keila Batista Alves, Nathalia and 
Cristina Sanches, on “Is quality of life associated with 
compliance to pharmacotherapy in patients with chronic 
kidney disease undergoing maintenance hemodialysis” it 
was found that the domain with lowest average score were 
physical role functioning (0.0) and emotional role 
functioning (33.3%). On the other hand, the domain social 
role functioning showed best average score (100.0%)5. 
In our study it was found that as shown in Table 13, younger 
adults of age group 20-29 years were having better QOL 
compared to older age. 
Correlation between medication adherence and quality of 
life was done using Pearson correlation. Although the quality 
of life score had slight association with medication 
adherence, the change was not statistically significant 
because the mean difference was found to be low. 
Patient’s adherence to medication was assessed before and 
after patient counselling using paired Sample-T test as 
shown in Table 14. It was found that patients adherence to 
medication was improved after patient education through 
patient counselling. Out of 140 patients, prior to patient 
education during baseline visits forgetfulness was found in 
14 patients, which was reduced to 5 patients, carelessness 
was found in 11 patients which was reduced to 5 patients, 
fear of side effects was found in 7 patients which was 
reduced to 0 patients and lack of information was found in 6 
patients which was reduced to 1 patient after patient 
education through counselling. Thus, the study was found to 
be statistically significant (p value< 0.05). 
In a study conducted by Anurodh Ghimirey, Binaya Sapkota, 
Sweta Shrestha on “Evaluation of pharmacist counselling in 
improving knowledge, attitude, and practice in chronic 
kidney disease patients”; it was observed that mean 
knowledge score of the case group after intervention was 
significantly higher than that before intervention. The 
knowledge score increased from 8.06 ± 4.25 to 8.22 ± 4.13 in 
patients, the change was not statistically significant14. 
CONCLUSION 
Medication adherence is a dynamic behaviour and need 
constant monitoring. Non adherence to medication is very 
prevalent among CKD patients in India, which further 
increases with duration of treatment. Low medication 
adherence was significantly associated with mortality and 
disease progression. Non compliance to drug therapy also 
worsens the quality of life. 
It was found that patients adherence to medication was 
improved from 80 to 85% after patient counselling, thus this 
study demonstrates that patients adherence to medication 
can be improved by educating the patient through 
counselling. 
We found that forgetfulness; carelessness and concern about 
cost were the major reasons contributing for medication non 
adherence. HTN was the most common co-morbidity among 
CKD patients. 
An adequate education through patient counselling was 
carried out to the patient to improve their medication 
adherence and to make them understand the importance of 
being adhered to the medication. The domain with highest 
average score was emotional well being and lowest average 
score was role limitation due to physical health. Patient’s 
quality of life was slightly improved after patient 
counselling. 
From this study we analysed the reasons contributing for 
medication non adherence and with the help of patient 
counselling we were able to improve medication adherence 
and improve quality of life in patients with CKD. 
Limitations 
KDQOL assessment was tedious and time consuming due to 
communication barriers and patient compliance. 
Future Directions 
 If the study is multicentered, more reproducible data 
can be obtained for a larger population. 
 If the study is carried out for a longer period of time 
more reliable data can be obtained. 
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